The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
(Approval lapsed) ATENZA methylphenidate hydrochloride 27mg prolonged-release tablets (Spain)
Section 19A approved medicine
(Approval lapsed) ATENZA methylphenidate hydrochloride 27mg prolonged-release tablets (Spain)
Section 19A approval holder
Arrotex Pharmaceuticals Pty Ltd ABN 30 605 552 234
Phone
1800 195 055
Approved until
Status
Expired
Medicines in short supply/unavailable
CONCERTA methylphenidate hydrochloride 27mg modified release tablet bottle - ARTG 124502
METHYLPHENIDATE-TEVA XR methylphenidate hydrochloride 27 mg modified release tablet bottle - ARTG 370911
METHYLPHENIDATE-TEVA XR methylphenidate hydrochloride 27 mg modified release tablet bottle - ARTG 370911
Indication(s)
Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment should be commenced by a specialist.
Images
